Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA, Demattos R.
Siemers ER, et al.
Alzheimers Dement. 2016 Feb;12(2):110-120. doi: 10.1016/j.jalz.2015.06.1893. Epub 2015 Aug 1.
Alzheimers Dement. 2016.
PMID: 26238576
Free article.
Clinical Trial.